← All science articles

· 2 min read

Defibrotide Shown to Curb Platelet Clumping and Boost Clot-Dissolving Proteins

By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Havdis Arctic PDRN95c against a stormy Norwegian coastline

Based on the PubMed abstract — the full text of this paper was not freely available.

Ulutin and colleagues, writing in Advances in Experimental Medicine and Biology (1990), summarize years of laboratory, animal and clinical work on defibrotide, a single-stranded polydeoxyribonucleotide made by controlled breakdown of DNA from mammalian lungs. The paper concerns blood clotting, not skin or tissue regeneration: it covers how the compound acts on blood vessel linings and on platelets, the cell fragments that start clot formation.

The authors report that defibrotide increases t-PA, a protein that helps dissolve clots, while lowering PAI, a protein that blocks that process. It also raises production of PGI2, a signaling molecule that keeps platelets from clumping, increases platelet c-AMP, and lowers two markers of platelet activation, MDA and TXB2. In laboratory tests and in rats, defibrotide blocked platelet aggregation and prevented clot formation after surgical reconnection of blood vessels. In animal experiments it also raised levels of the clot-regulating proteins C and S and acted together with heparin.

The authors state that defibrotide showed benefit in human patients with deep vein thrombosis, peripheral vascular disease, stroke and thromboembolism, citing their own prior publications. As a summary paper, it gives no new patient counts, doses or trial design here, and says nothing about skin biology, wound healing or safety data.

Our reflection

Defibrotide's long record shows that polydeoxyribonucleotides, built from controlled breakdown of DNA into defined fragments, can produce measurable, reproducible biological effects, here on clotting proteins and platelet signaling rather than skin. That history comes from pharmacology, not skincare, but it is part of the broader scientific lineage this molecule class comes from. At Havdis, we see such groundwork as part of the foundation underlying today's PDRN research.

Source

Ulutin ON, Balkuv-Ulutin S, Ugur MS, Ulutin T, Ozsoy Y, Cizmeci G (1990). Advances in experimental medicine and biology.

Read the paper on PubMedDOI: 10.1007/978-1-4615-3806-6_46

This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.

From research to ingredient

Developing with PDRN? Let’s talk.